PIK3CA, and PTEN Aberrations in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors: Experience with 1,656 Patients at MD Anderson Cancer Center

Despite a wealth of preclinical studies, it is unclear whether PIK3CA or PTEN gene aberrations are actionable in the clinical setting. Of 1,656 patients with advanced, refractory cancers tested for PIK3CA or PTEN abnormalities, PIK3CA mutations were found in 9% (146/1,589), and PTEN loss and/or muta...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cell Rep
Prif Awduron: Janku, Filip, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Naing, Aung, Falchook, Gerald S., Tsimberidou, Apostolia M., Stepanek, Vanda M., Moulder, Stacy L., Lee, J. Jack, Luthra, Rajyalakshmi, Zinner, Ralph G., Broaddus, Russell R., Wheler, Jennifer J., Kurzrock, Razelle
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2014
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4409143/
https://ncbi.nlm.nih.gov/pubmed/24440717
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2013.12.035
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg